Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) PT at $30.00

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given an average recommendation of “Buy” by the six analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report on the stock in the last year is $30.00.

Several analysts have recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. HC Wainwright upgraded Avalo Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Monday, June 2nd. Piper Sandler assumed coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. Jefferies Financial Group assumed coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 target price on the stock.

Avalo Therapeutics Stock Up 5.7%

Shares of AVTX stock opened at $4.82 on Friday. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $16.00. The firm has a 50 day moving average of $4.52 and a 200-day moving average of $6.81.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.18). Research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its stake in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth $80,000. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth $145,000. Finally, Northern Trust Corp bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth $168,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.